The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | The FORTE trial: the value of sustained MRD negativity
Jesús San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the value of sustained minimal residual disease (MRD) negativity in the context of the FORTE trial (NCT02203643) for patients with newly diagnosed multiple myeloma. The FORTE trial evaluated the safety and efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd), or lenalidomide and dexamethasone (KRd) followed by autologous stem cell transplantation (ASCT) or 12 cycles of carfilzomib combined with dexamethasone and lenalidomide. The trial found the rate of MRD negativity to be similar with KRd consolidation with or without transplantation, however the progression-free survival (PFS) was longer in the KRd plus transplant arm. Dr Miguel highlights that this is due to sustained MRD negativity, which demonstrates the value of maintenance therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
